Baseline clinical features in patients with and without CI-AKI
| Variables | CI-AKI | p Value | |
|---|---|---|---|
| Yes (n=85) | No (n=1930) | ||
| Demographics | |||
| Age (years), mean±SD | 56.14±17.84 | 51.71±16.68 | 0.017 |
| Women, n (%) | 44 (51.8) | 951 (49.3) | 0.882 |
| Weight (kg), mean±SD | 57.39±10.77 | 57.78±15.73 | 0.819 |
| Medical history, n (%) | |||
| Smoking | 8 (9.4) | 144 (7.5) | 0.505 |
| Hypertension | 27 (31.8) | 581 (30.1) | 0.928 |
| Diabetes | 16 (18.8) | 264 (13.7) | 0.180 |
| Prior cerebrovascular disease | 4 (4.7) | 194 (10.1) | 0.105 |
| Type of stroke | |||
| Ischemic stroke, n (%) | 81 (95.3) | 1739 (90.1) | |
| Laboratory findings | |||
| Baseline SCr (mol/L), mean±SD | 103.02±35.88 | 97.05±30.90 | 0.084 |
| Baseline eGFR (mL/min/1.73 m2), mean±SD | 57.30±22.46 | 64.82±34.09 | 0.044 |
| Baseline eGFR <60 mL/min/1.73 m2, n (%) | 53 (62.4) | 961 (49.8) | 0.023 |
| Proteinuria, n (%) | 12 (14.1) | 53 (2.7) | <0.001 |
| Anemia, n (%) | 31 (36.5) | 143 (7.4) | <0.001 |
| Hypoalbuminemia, n (%) | 4 (4.7) | 120 (6.2) | 0.570 |
| Hyperuricemia, n (%) | 51 (60) | 1099 (56.9) | 0.557 |
| High LDL, n (%) | 8 (9.4) | 279 (14.5) | 0.193 |
| Hypercholesterolemia, n (%) | 9 (10.6) | 279 (14.5) | 0.319 |
| Hypertriglyceridemia, n (%) | 27 (31.8) | 665 (34.5) | 0.609 |
| Fasting glucose (mmol/L), mean±SD | 5.90±2.55 | 5.73±1.94 | 0.437 |
| Neurological deficit scoring | |||
| NIHSS, median | 15 (14.17) | 1 (1.3) | <0.001 |
| Medicine, n (%) | |||
| Hydration | 21 (24.7) | 580 (30.1) | 0.292 |
| Statins | 17 (20.0) | 328 (17.0) | 0.472 |
| ACEI/ARB | 37 (43.5) | 832 (43.1) | 0.939 |
| Diuretics | 66 (77.6) | 1624 (84.1) | 0.111 |
| Antiplatelet agents | 53 (62.4) | 1108 (57.4) | 0.367 |
| Anticoagulants | 31 (36.5) | 730 (37.8) | 0.801 |
| Procedural characteristics | |||
| Contrast type: Ultravist 370, n (%) | 79 (92.9) | 1859 (96.3) | 0.112 |
| Contrast volume (ml), mean±SD | 71.18±27.05 | 69.11±16.76 | 0.487 |
| Contrast exposure time > 30 min, n (%) | 36 (42.4) | 816 (42.3) | 0.989 |
| No endovascular therapy, n (%) | 63 (74.1) | 1459 (75.6%) | 0.760 |
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; CI-AKI, contrast-induced acute kidney injury; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; NIHSS, National Institute of Health Stroke Scale; SCr, serum creatinine.